The US Cabozantinib Market is supported by a well-established oncology care infrastructure and widespread access to specialized cancer treatment. The country's strong focus on precision medicine also supports the clinical evaluation and use of targeted therapies. The Cabozantinib Market was valued at US$ 1.46 billion in 2025 and is expected to reach US$ 2.67 billion by 2034, registering a CAGR...